Recently approved drug for migraine prophylaxis is:
**Core Concept**
The question is testing knowledge of pharmacological interventions for migraine prophylaxis. Migraine prophylaxis involves the use of medications to prevent or reduce the frequency and severity of migraine attacks. The underlying principle being tested is the identification of a recently approved medication for this indication.
**Why the Correct Answer is Right**
The correct answer is Galcanezumab, a calcitonin gene-related peptide receptor (CGRP) antagonist. Galcanezumab works by binding to the CGRP receptor, thereby preventing the action of CGRP, which is involved in the pathophysiology of migraine. CGRP is a key player in the development of migraine, and blocking its action has been shown to be effective in preventing migraine attacks.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it is not a well-known medication for migraine prophylaxis.
* **Option B:** This option is incorrect because it is not a recently approved medication for migraine prophylaxis.
* **Option C:** This option is incorrect because it is not a medication that has been specifically approved for migraine prophylaxis.
**Clinical Pearl / High-Yield Fact**
Galcanezumab is a monoclonal antibody that has been approved for the preventive treatment of migraine in adults. It is administered via subcutaneous injection and has been shown to be effective in reducing the frequency of migraine attacks.
**Correct Answer: C. Galcanezumab**